Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated July 6, 2022, reports the results of a General Meeting held on that date. The primary business context is the shareholder approval of the proposed demerger of Haleon plc (GSK's consumer health business) and a subsequent share consolidation for GSK.
Key Financial Metrics
The filing text does not provide financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance actions and the mechanics of the demerger.
Material Changes and Corporate Actions
- Shareholder Approval: Shareholders passed two resolutions with overwhelming support:
- Demerger Resolution: 99.81% voted in favor (3,568,610,751 votes for vs. 6,794,940 against).
- Related Party Transactions Resolution: 99.77% voted in favor (3,565,834,534 votes for vs. 8,056,152 against).
- Demerger Completion: The demerger of Haleon is expected to complete on July 18, 2022, with Haleon shares admitted to trading on the London Stock Exchange (LSE) at 8:00 am UK time.
- Share Consolidation: The GSK Share Consolidation is expected to become effective after 8:00 pm UK time on July 18, 2022.
- Board Appointment: Dr. Vishal Sikka's appointment as a Non-Executive Director becomes effective on July 18, 2022.
Guidance, Outlook, and Risks
The filing includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ due to risks described in the 2021 Annual Report on Form 20-F, Q1 2022 results, and the ongoing impacts of the COVID-19 pandemic. Specific outlooks for Haleon are referenced in the "Haleon Capital Markets Day" presentation dated February 28, 2022.
Investor Verification Checklist
- Verify the ex-dividend date for GSK shares is Monday, July 18, 2022, to determine entitlement to Haleon shares.
- Confirm the Shareholder Record Time is 6:00 pm UK time on Friday, July 15, 2022.
- Note that GSK ADS issuance and cancellation books will be closed from July 14 to July 25, 2022, preventing conversion between ADSs and underlying shares during this period.
- Check the timetable for the commencement of dealings in New GSK Shares on the LSE (Tuesday, July 19, 2022) and Haleon ADSs on the NYSE (Friday, July 22, 2022).
- Review the Circular to Shareholders (published June 1, 2022) for full details on the demerger mechanics and related party transactions.